Diabetes Clinical Trial
Official title:
A Randomized, Double Blind Placebo Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZYGK1, a Novel Glucokinase Activator, Following Oral Administration in Healthy Volunteers
The purpose of this study is to determine (1) whether ZYGK1 is safe and well tolerated, (2) the pharmacokinetics (what body does to ZYGK1) and (3) pharmacodynamics (what drugs does to the body) in the healthy and diabetic subject.
Status | Suspended |
Enrollment | 96 |
Est. completion date | |
Est. primary completion date | December 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: 1. Age: 18-45 years 2. Mentally, physically, and legally eligible to give informed consent 3. Male and female volunteers weighing between 50-75 kg and 45-75 kg (4) respectively. 4. Ability to communicate effectively with the study personnel 5. Willingness to adhere to the protocol requirements 6. For gender effect study, only females with history of sterility or at least one year menopause or use of long acting nonhormonal contraceptive measures (e.g., intrauterine device) will be recruited. 7. At least one panel, in single ascending dose and multiple ascending dose will include subjects with type 2 diabetes as defined by American Diabetes Association Exclusion Criteria: 1. Presence or history of hypersensitivity to any of the active or inactive ingredients of ZYGK1 formulation 2. Presence or history of pancreatitis at any time (Serum Amylase/Serum Lipase more than upper normal limit (UNL)) 3. Presence or history of severe gastrointestinal disease in the last 6 months 4. Presence or history of renal insufficiency at any time (serum creatinine >UNL) 5. Active liver disease and/or liver transaminases greater than 1.5 X UNL 6. History or presence of other systemic disorders or diseases (e.g., respiratory, gastrointestinal, endocrine, immunological, dermatological, neurological, psychiatric disease or any other body system involvement) 7. Abnormal bleeding time (BT), clotting time (CT), prothrombin time (PT), and activated partial prothrombin time (APTT) 8. History or presence of any medication in the last 14 days 9. History or presence of significant alcoholism or drug abuse within the past 1 year 10. History or presence of significant smoking (more than 10 cigarettes per day) or consumption of tobacco products (more than 10 times per day) 11. Difficulty with donating blood 12. Systolic blood pressure more than 140 mmHg and less than 100 mmHg and diastolic blood pressure more than 90 mmHg and less than 60 mmHg 13. Pulse rate less than 60 minute and more than 100/minute 14. Any clinically significant laboratory findings during screening 15. History or presence of any clinically significant electrocardiogram (ECG) abnormalities during screening 16. Major illness and/or major surgery in last 3 months 17. Volunteers who have participated in any drug research study other than the present trial within past 3 months 18. Volunteers who have donated one unit (350 ml) of blood in the past 3 months |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
India | Clinical R&D, Zydus Research Center, Cadila Healthcare Limited, NH No.8, Moraiya | Ahmedabad | Gujarat |
Lead Sponsor | Collaborator |
---|---|
Cadila Healthcare Limited |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and tolerability | Safety and tolerability for- Plan I, Plan III and Plan IV [Time frame: up to Day 8] Plan II [Time frame: upto Day 14] Frequency of adverse events will be assessed at each dose level. |
Upto 14 Days | Yes |
Secondary | Pharmacokinetics | Pharmacokinetics after oral administration of ZYGK1 in Plan I, III and IV: [Time frame: 0.25 - 168 hrs post drug administration] Plan II: [Time frame:Day 1: 0.25 - 12 hours, Day 2-6: 0, 2, 4 Hours, Day: 0.25-168 hours post drug administration] Effects of food on the pharmacokinetics will be assessed in healthy subjects. |
7 Days | No |
Secondary | Pharmacodynamics | Plasma glucose, serum insulin, C-peptide and glucagoan estimate - Plane I and Plan III [Time frame: Day 0 and Day 1: upto 4 hours post oral glucose 75 grams] Plan II [Time frame: Day 0, Day 1 and Day 7: upto 4 hours post oral glucose 75 grams] Plan IV: [Time frame: Period 2: Day 0 and Day 1: upto 4 hours post meal] |
7 Days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05594446 -
Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
|
||
Completed |
NCT03975309 -
DHS MIND Metabolomics
|
||
Completed |
NCT01855399 -
Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes
|
N/A | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
Recruiting |
NCT05007990 -
Caregiving Networks Across Disease Context and the Life Course
|
||
Active, not recruiting |
NCT04420936 -
Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program
|
N/A | |
Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
Completed |
NCT04903496 -
Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
|
||
Completed |
NCT01437592 -
Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT03390179 -
Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Recruiting |
NCT05294822 -
Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes
|
N/A | |
Completed |
NCT04427982 -
Dance and Diabetes/Prediabetes Self-Management
|
N/A | |
Completed |
NCT02356848 -
STEP UP to Avert Amputation in Diabetes
|
N/A | |
Completed |
NCT03292185 -
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
|
Phase 1 | |
Active, not recruiting |
NCT05477368 -
Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes
|
N/A | |
Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 |